Company · CIK 0002058707 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Attovia Therapeutics, Inc. · ATTO
Insider activity reported against this company. All insider holders · Files at: ATTO. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 CForm 4/A → | Aug 28, 5:38 pm EDT | Colin WalshDirector | 2,435,632 | — | — | 2,520,632 | — | |
| Aug 6, 2026 CForm 4/A → | Aug 28, 5:38 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 2,435,632 | — | — | 2,520,632 | — | |
| Aug 6, 2026 CForm 4 → | Aug 13, 9:52 pm EDT | Colin WalshDirector | 2,435,632 | — | — | 2,520,632 | — | late amended |
| Aug 6, 2026 CForm 4 → | Aug 13, 9:51 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 2,435,632 | — | — | 2,520,632 | — | late amended |
| Aug 6, 2026 CForm 4 → | Aug 10, 4:30 pm EDT | Deep Track Biotechnology Master Fund, Ltd. +210% Owner | 1,957,138 | — | — | 1,957,138 | — | |
| Aug 6, 2026 PForm 4 → | Aug 10, 4:12 pm EDT | venBio Global Strategic Fund IV, L.P.10% Owner | 382,352 | $17.00 | $6,499,984 | 4,181,367 | +10.1% | |
| Aug 6, 2026 CForm 4 → | Aug 10, 4:12 pm EDT | venBio Global Strategic Fund IV, L.P.10% Owner | 3,799,015 | — | — | 3,799,015 | — | |
| Aug 6, 2026 PForm 4 → | Aug 7, 9:47 pm EDT | Redmile Group, LLC +210% Owner | 600,000 | $17.00 | $10,200,000 | 1,182,854 | +103% | |
| Aug 6, 2026 CForm 4 → | Aug 7, 9:47 pm EDT | Redmile Group, LLC +210% Owner | 782,854 | — | — | 782,854 | — | |
| Aug 6, 2026 PForm 4 → | Aug 7, 3:45 pm EDT | Sanofi10% Owner | 300,000 | $17.00 | $5,100,000 | 1,082,855 | +38.3% | |
| Aug 6, 2026 CForm 4 → | Aug 7, 3:45 pm EDT | Sanofi10% Owner | 782,855 | — | — | 782,855 | — | |
| Aug 6, 2026 PForm 4 → | Aug 6, 5:35 pm EDT | Frazier Life Sciences XI, L.P. +210% Owner | 588,235 | $17.00 | $9,999,995 | 6,154,213 | +10.6% | |
| Aug 6, 2026 CForm 4 → | Aug 6, 5:35 pm EDT | Frazier Life Sciences XI, L.P. +210% Owner | 5,490,629 | — | — | 5,565,978 | — | |
| Aug 5, 2026 SForm 4/A → | Aug 28, 5:38 pm EDT | Colin WalshDirector | 105,807 | $21.28 | $2,251,658 | 0 | −100% | |
| Aug 5, 2026 PForm 4/A → | Aug 28, 5:38 pm EDT | Colin WalshDirector | 585,000 | $17.58 | $10,285,000 | 3,020,632 | +24.0% | |
| Aug 5, 2026 SForm 4/A → | Aug 28, 5:38 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 105,807 | $21.28 | $2,251,658 | 0 | −100% | |
| Aug 5, 2026 PForm 4/A → | Aug 28, 5:38 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 585,000 | $17.58 | $10,285,000 | 3,020,632 | +24.0% | |
| Aug 5, 2026 SForm 4 → | Aug 13, 9:52 pm EDT | Colin WalshDirector | 105,807 | $21.28 | $2,251,658 | 0 | −100% | late amended |
| Aug 5, 2026 PForm 4 → | Aug 13, 9:52 pm EDT | Colin WalshDirector | 585,000 | $17.58 | $10,285,000 | 3,020,632 | +24.0% | late amended |
| Aug 5, 2026 SForm 4 → | Aug 13, 9:51 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 105,807 | $21.28 | $2,251,658 | 0 | −100% | late amended |
| Aug 5, 2026 PForm 4 → | Aug 13, 9:51 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 585,000 | $17.58 | $10,285,000 | 3,020,632 | +24.0% | late amended |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 CForm 4 → | Aug 13, 9:52 pm EDT | Colin WalshDirector | 22,627,105 | — | — | 0 | — | late amended |
| Aug 6, 2026 CForm 4 → | Aug 13, 9:51 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 22,627,105 | — | — | 0 | — | late amended |
| Aug 6, 2026 CForm 4 → | Aug 10, 4:30 pm EDT | Deep Track Biotechnology Master Fund, Ltd. +210% Owner | 18,181,818 | — | — | — | — | |
| Aug 6, 2026 CForm 4 → | Aug 10, 4:12 pm EDT | venBio Global Strategic Fund IV, L.P.10% Owner | 35,292,854 | — | — | 0 | — | |
| Aug 6, 2026 CForm 4 → | Aug 7, 9:47 pm EDT | Redmile Group, LLC +210% Owner | 782,854 | — | — | 0 | — | |
| Aug 6, 2026 CForm 4 → | Aug 7, 3:45 pm EDT | Sanofi10% Owner | 782,855 | — | — | 0 | — | |
| Aug 6, 2026 CForm 4 → | Aug 6, 5:35 pm EDT | Frazier Life Sciences XI, L.P. +210% Owner | 51,007,956 | — | — | 0 | — | |
| Aug 5, 2026 CPForm 4/A → | Aug 28, 5:38 pm EDT | Colin WalshDirector | 22,732,912 | $21.25 | $2,248,074 | 105,807 | — | |
| Aug 5, 2026 CPForm 4/A → | Aug 28, 5:38 pm EDT | GOLDMAN SACHS GROUP INC +7Other | 22,732,912 | $21.25 | $2,248,074 | 105,807 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:17 pm EDT | Angie YouDirector | 27,000 | — | — | 27,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:17 pm EDT | Mitchell GoldDirector | 27,000 | — | — | 27,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:16 pm EDT | Zaneta OdrowazChief Business Officer | 140,000 | — | — | 140,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:15 pm EDT | Petter VeibyChief Scientific Officer | 140,000 | — | — | 140,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:14 pm EDT | Hubert ChenChief Medical Officer | 140,000 | — | — | 140,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:13 pm EDT | Attovia Therapeutics, Inc.Chief Financial Officer | 140,000 | — | — | 140,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:11 pm EDT | Attovia Therapeutics, Inc.President and CEO, Director | 538,300 | — | — | 538,300 | — |
Filed by this entity as an insider elsewhere — common stock
No reported common-stock activity in this period.
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 AForm 4 → | Aug 6, 5:13 pm EDT | Attovia Therapeutics, Inc.ATTO | 140,000 | — | — | 140,000 | — | |
| Aug 4, 2026 AForm 4 → | Aug 6, 5:11 pm EDT | Attovia Therapeutics, Inc.ATTO | 538,300 | — | — | 538,300 | — |